INmune Bio (NASDAQ: INMB), a diversified clinical-stage
immunology company focused on developing treatments that harness the patient’s
innate immune system to combat disease, is currently developing drug candidates
INKmune and INB03, which may be used to treat cancer, and XPro1595, which
targets neuroinflammation as a cause of Alzheimer’s disease. An article further
discussing the company reads, “XPro1595 targets the microglial immune cells of
the brain that are activated in many Alzheimer’s disease patients. These
microglial cells are a cause of neuroinflammation that can kill nerve cells and
promote synaptic dysfunction — the cause of dementia in Alzheimer’s. A phase I
clinical trial in patients with Alzheimer’s disease, supported by the
Alzheimer’s Association grant, is expected to be initiated in the summer of
2019. . . . Upcoming catalysts for INmune Bio include advancements in several
clinical trials featuring INB03 and INKmune — both of which are focused on
‘taking the brakes off’ the body’s innate immune system to become a powerful
weapon in the fight against cancer. INB03 is a checkpoint inhibitor that
targets cells resistant to immunotherapy to instead become therapeutically
effective; INKmune primes a patient’s own natural killer cells to move from a
resting state to an active state to attack and eliminate residual disease
(lingering cancer cells) after cancer therapy.”
To view the full article, visit http://ibn.fm/Ere6I
About INmune Bio Inc.
INmune Bio Inc. (NASDAQ: INMB) is a publicly traded,
clinical-stage biotechnology company developing therapies targeting the innate
immune system to fight disease. INmune Bio is developing three product
platforms: two products that re-engineer the patient’s innate immune system’s
response to cancer and one product to treat neuroinflammation that is currently
focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell
therapeutic that primes the patient’s NK cells to attack minimal residual
disease, the remaining cancer cells that are difficult to detect, which often
cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which
often cause resistance to immunotherapy, such as anti-PD-1 checkpoint
inhibitors. XPro1595 targets neuroinflammation, which causes microglial
activation and neuronal cell death. INmune Bio’s product platforms utilize a
precision medicine approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation. To learn more, please
visit www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
